2021, Volume 10
2020, Volume 9
2019, Volume 8
2018, Volume 7
2017, Volume 6
2016, Volume 5
2015, Volume 4
2014, Volume 3
2013, Volume 2
2012, Volume 1
Volume 10 , Issue 6 , November 2021 , Pages: 191 - 196
Hyporesponsiviness to Erythropoietin Therapy in End Stage Renal Disease Patients on Regular Haemodialysis
Jawad Kadhem Manuti, Medical College, AL-Nahrain University, Baghdad, Iraq
Ali Ghafil Alwan, Medical College, AL-Nahrain University, Baghdad, Iraq
Muhammed Jassim Abd Ali, Medical College, AL-Nahrain University, Baghdad, Iraq
Received: Jun. 20, 2021;       Accepted: Jul. 2, 2021;       Published: Nov. 23, 2021
DOI: 10.11648/j.cmr.20211006.14        View        Downloads  
Background: Many factors can alter the response to erythropoietin treatment and approximately 5–10% of patients present an evident resistance in response to erythropoietin therapy. These include: iron deficiency, inflammation, infections, malignancy, dialysis, blood loss, hyperparathyroidism, aluminum toxicity and vitamin B12 or folate deficiencies. Objective: To evaluate and search for causative factors that predispose to Anemia resistance to erythropoietin therapy in End stage renal failure patients on regular hemodialysis. Patients and methods: This is descriptive prospective study enrolling 350 patients with End stage renal disease on regular hemodialysis, during January 2019 to January 2020 at Al-Emamain Al-Kadumian Medical City / Nephrology unit. 117 (44 female and 73 male) patients enrolled in this study whom met the inclusion criteria: Hgb level below 11 mg / dl despite adequate erythropoietin dose, regular adequate HD, Iron and folic acid supplementation. Amonthly bases measurement of CBC, CRP, S. Albumin, S. Ca, S. Phos, S. PTH, S. Ferritin and Transferrin Saturation were obtained. Results: 39% of patients have anemia resistance to erythropoietin. 48.7% of cases were taking Angiotensin converting enzyme inhibitors or angiotensin receptor blockers while 51.3% not. Hemoglobin level was significantly affected with ACEi or ARBs drugs use 8.20±1.17 mg/dl with drug use versus 8.95±0.82 mg/dl without ACEi or ARBs (p value <0.001). Hemoglobin level average was 7.85±1.01 mg/dl in female patients while 8.99±0.87 in male patients (p value<0.001). The mean WBC 7799 ± 2278 ×103/mm3 shows negative effect on Hgb level (p value < 0.001), The Hgb level was negatively corelated with serum ferritin level (mean S. ferritin 592.9577 ± 270.707ng/ml) (p value 0.031). CRP level negatively corelate with Hgb level (p value< 0.001) while Albumin Level Positively corelated (p value < 0.001). Regarding Parathyroid, S. Ca and S. Pho level impacts on Hgb level shows negatively correlate of Hgb with PTH (mean 691.7144±324.66 pg/ml)(p< 0.001) and S. Pho (mean 5.4637 ± 1.01585 mg/dl) (p value 0.024) and positive correlate with S. Ca (8.40744± 0.660188 mg/dl) (p value 0.023). Conclusion: The level of hemoglobin response to erythropoietin is significantly affected by Gender (female require higher dose), ACEi and ARBs treatment, WBC, CRP, Serum Albumin, Serum Calcium, Serum Ferritin, Serum Phosphorus and Serum Parathyroid hormone.
End Stage Renal, Hemodialysis, Erythropoietin
To cite this article
Jawad Kadhem Manuti, Ali Ghafil Alwan, Muhammed Jassim Abd Ali, Hyporesponsiviness to Erythropoietin Therapy in End Stage Renal Disease Patients on Regular Haemodialysis, Clinical Medicine Research. Vol. 10, No. 6, 2021, pp. 191-196. doi: 10.11648/j.cmr.20211006.14
Copyright © 2021 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License ( which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
[ 1 ]
Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012; 23 (10): 1631–4.
[ 2 ]
Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Albumin, Serum Calcium have positive correlation on EPO responsiveness. while Guideline for Anemia in Chronic Kidney Disease. Kidney Int Suppl [Internet]. 2012; 2 (4): 279–335. Available from:
[ 3 ]
Alves MT, Vilaça SS, Carvalho M das G, Fernandes AP, Dusse LMSA, Gomes KB. Resistance of dialyzed patients to erythropoietin. Rev Bras Hematol Hemoter. 2015; 37 (3): 190–7.
[ 4 ]
John Feehally JFT. Comprehensive Clinical Nephrology sixth edition. 2019. 958 p.
[ 5 ]
Alves MT, Vilaça SS, Godoi LC, Júnior LR, Carvalho M das G, Silva F de S, et al. Parvovirus B19 (B19) and cytomegalovirus (CMV) infections and anti-erythropoietin (anti-EPO) antibodies in patients on dialysis hyporesponsive to erythropoietin therapy. Clin Chim Acta [Internet]. 2014; 431: 52–7. Available from:
[ 6 ]
Bamgbola OF. Pattern of resistance to erythropoietin-stimulating agents in chronic kidney disease. Kidney Int [Internet]. 2011; 80 (5): 464–74. Available from:
[ 7 ]
Drüeke TB. Anemia treatment in patients with chronic kidney disease. N Engl J Med. 2013; 368 (4): 387–9.
[ 8 ]
Wish JB. Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol. 2006; 1 (Supplement 1): S4–8.
[ 9 ]
Gaweda AE, Goldsmith LJ, Brier ME, Aronoff GR. Iron, inflammation, dialysis adequacy, nutritional status, and hyperparathyroidism modify erythropoietic response. Clin J Am Soc Nephrol. 2010; 5 (4): 576–81.
[ 10 ]
Stević N, Stefanović N, Veličković - Radovanović R, Apostolović B, Paunović K, Cvetković M, et al. T He Influence of Ace Inhibitors Treatment on Anemia Parameters in Patients on Maintenance Hemodialysis. Acta Medica Median. 2017; 56 (3): 107–15.
[ 11 ]
Iodice C, Balletta MM, Minutolo R, Giannattasio P, Tuccillo S, Bellizzi V, et al. Maximal suppression of renin-angiotensin system in nonproliferative glomerulonephritis. Kidney Int. 2003; 63 (6): 2214–21.
[ 12 ]
Macdougall IC, Roger SD, De Francisco A, Goldsmith DJA, Schellekens H, Ebbers H, et al. Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights. Kidney Int. 2012; 81 (8): 727–32.
[ 13 ]
Shin S-K, Moon SJ, Ha SK, Jo Y-I, Lee T-W, Lee YS, et al. Immunogenicity of recombinant human erythropoietin in Korea: a two- year cross-sectional study. Biologicals. 2012; 40 (4): 254–61.
[ 14 ]
Jeong K-H, Lee T-W, Ihm C-G, Lee S-H, Moon J-Y. Polymorphisms in two genes, IL-1B and ACE, are associated with erythropoietin resistance in Korean patients on maintenance hemodialysis. Exp Mol Med. 2008; 40 (2): 161.
[ 15 ]
Icardi A, Paoletti E, De Nicola L, Mazzaferro S, Russo R, Cozzolino M. Renal anaemia and EPO hyporesponsiveness associated with vitamin D deficiency: The potential role of inflammation. Nephrol Dial Transplant. 2013; 28 (7): 1672–9.
[ 16 ]
Farahat HG, Marey HMG, Badawi NM, Allam HK, Issa MMM. Prevalence of occult refractive errors in primary school students. Menoufia Med J. 2017; 31 (1): 267–72.
[ 17 ]
Coronado Daza JA, Cuchi GU. Gender Differences in Dose of Erythropoietin to Maintain Hemoglobin Target in Hemodialysis Patients. Indian J Nephrol [Internet]. 2019; 29 (3): 160–5. Available from:
[ 18 ]
Karaboyas A, Morgenstern H, Fleischer NL, Vanholder RC, Dhalwani NN, Schaeffner E, et al. Inflammation and Erythropoiesis-Stimulating Agent Response in Hemodialysis Patients: A Self-matched Longitudinal Study of Anemia Management in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Med [Internet]. 2020; XX: 1–11. Available from:
[ 19 ]
Samavat S, Nafar M, Khoshdel A, Alipour-Abedi B. Factors contributing to erythropoietin hyporesponsiveness among hemodialysis patients: A cross-sectional multicenter study. Nephrourol Mon. 2017; 9 (3).
[ 20 ]
Yokoyama K, Fukagawa M, Akiba T, Nakayama M, Otoguro T, Yamada K, et al. Ferritin Elevation and Improved Responsiveness to Erythropoiesis-Stimulating Agents in Patients on Ferric Citrate Hydrate. Kidney Int Reports [Internet]. 2017; 2 (3): 359–65. Available from:
Browse Journals by Subject